Foodborne Botulism

Version	Summary	Created by	Modification	Content Size	Created at	Operation
1		Davide Lonati	--	2763	2022-09-02 03:31:06	\|
2	format correct	Catherine Yang	Meta information modification	2763	2022-09-02 03:34:47	\|

This entry is adapted from the peer-reviewed paper 10.3390/toxins12080509

Botulinum neurotoxins (BoNTs) produced by Clostridia species are the most potent identified natural toxins. Classically, the toxic neurological syndrome is characterized by an (afebrile) acute symmetric descending flaccid paralysis. The most know typical clinical syndrome of botulism refers to the foodborne form. All different forms are characterized by the same symptoms, caused by toxin-induced neuromuscular paralysis.

botulism diagnosis treatment food toxicity

1. Introduction

Botulinum neurotoxins (BoNTs) are the most powerful natural toxins and are mainly related to Clostridia species. These BoNTs can produce a life threatening neuroparalytic syndrome: the “botulism”. Classically, the clinical syndrome of human botulism is characterized by an acute, afebrile, symmetric descending flaccid paralysis. From the clinical point of view, this severe intoxication can be an emergency for which is required a prompt diagnosis and an early identification of sources. Moreover, every case of botulism may be also a public health emergency in case of suspected commercial product ingestion and immediately upon suspecting the diagnosis, the clinician should report the suspected case to Ministry of Health or to the national reference Agencies.

There may be different routes of exposure that characterize different forms of botulism: foodborne, infant and adult intestinal, wound, iatrogenic and inhalation botulism ^[1]^[2]. Botulism of unknown source is also mentioned by some authors ^[3]. All this different forms are clinically characterized by the same syndrome, due to the toxin-induced neuromuscular paralysis. Foodborne botulism is the most frequent form in EU and is the result of the ingestion of preformed BoNT-complexes in food ^[1]. In all different forms the toxic mechanism is related to effects of a specific xenobiotic, the BoNTs. There are seven known neurotoxins (types A–G), among them, the types A, B and E (rarely F) are toxic for humans, while type C and D mainly cause disease in animals, however human botulism cases have been described in literature as reviewed elsewhere ^[4]. Type G toxin was suspected in a case of wound botulism ^[5]. Recently, a chimeric BoNT type FA or HA (also called BoNT/H) was identified in a bivalent C. botulinum Bh strain responsible for infant botulism as well as type X was identified in a C. botulinum capable of producing type B toxin and isolated from an infant botulism case. In addition, BoNT-like toxins (BoNT/Wo and BoNT/En (BoNT/J) have been described ^[6].

2. Toxic Mechanism of Human Foodborne Botulism

The foodborne botulism form is well known in humans and is characterized by a neurological toxidrome consequence of the voluntary motor and autonomic cholinergic junctions’ blockade induced by the toxin. In this form, the preformed BoNT is ingested with food.

The different types of BoNT and the quantity ingested do not influence the toxic mechanism that result quite similar, this latest influences instead the onset (time) of the first clinical manifestations and the severity of the toxidrome.

C. botulinum and other BoNT-producing clostridia grow and produce toxin only when the food presents conditions that include an anaerobic milieu, a pH > 4.6, low salt and sugar content and a temperature of 4–45 °C ^[7]. Home-canned foods or traditional local food represent the major source of intoxication. History is extremely important to formulate or confirm the diagnosis of foodborne botulism and can be provided by obtaining (if possible) the last seven-day food history from the patient.

The bont-producing clostridia generate a polypeptide toxin (150,000 Daltons) that acts specifically on neuromuscular junctions and cholinergic sites within the autonomic nervous system (all ganglionic synapses and post-ganglionic parasympathetic synapses) by binding to receptors located on the presynaptic membrane. After that, by endocytosis and through a complex processes [e.g., translocation of light chain (Lc) into the cytosol and cleavage of soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs), by the metalloproteinase activity of the Lc] the toxin blocks the normal calcium-associated quantal release of acetylcholine from the presynaptic nerve terminals: this process is irreversible ^[8].

Acetylcholine molecules are normally contained in vesicles at presynaptic level in units named “quanta”. At first stage, acetylcholine vesicles are synthetized in the neuronal soma and subsequently transported at the terminals where they can be recycled several times. At the terminal level, quanta are contained in three different stores: primary store (immediately available) contains around 1.000 quanta and are nearest the presynaptic membrane; at secondary store (or mobilization store) the quanta (10.000) are available in 1–3 s; the tertiary store (reserve) contains more than 100.000 quanta and are located on the axon or neuronal soma. This physiological asset is completely altered by botulinum toxin.

From the clinical point of view, cranial nerves and muscles are primarily involved during the first neurological stage of intoxication. Moreover, the severity of ophthalmoparesis is considered a good indicator of the overall severity and progression of the intoxication. Probably the initial involvement of cranial nerves is due to three main reasons:

(1): the length of the neurons that innervate the cranial muscles is short, with consequent poor tertiary deposit (acetylcholine reserves are located in the axon or in the soma);
(2): facial muscles are continuously active (even during sleep), with a prevalence of phasic fibers, high neurotransmitter turnover and rapid internalization of toxin;
(3): few receptors are present at postsynaptic facial muscular membrane level that, more quickly, suffer from the lack of acetylcholine.

Recovery may occur only by formation of new axon terminals, with the regenerating axon (sprouting) forming contacts at the original synaptic sites. The time of recovery depends on entity of neuromuscular block associated with neurogenic atrophy (chemo-denervation) and on the regeneration speed of nervous terminals and of presynaptic membranes.

Central nervous system is not affected, and the toxin do not cross the placenta ^[9].

3. Treatment

Key points in the treatment of botulism are (i) the decontamination, (ii) the administration of the specific antidote and (iii) the support of respiratory function if necessary. There are only few differences related to the way of exposure.

3.1. Gastrointestinal Decontamination

Once excluded eventually contraindications, gastrointestinal decontamination should be performed in all case of foodborne botulism, in order to remove the spores and toxin from the gut. Most patients manifest the first clinical signs some days after consumption of contaminated meal; for this reason, gastric lavage (or induced emesis) should be considered only in cases in which the ingestion of possible contaminated food is recent. For all other cases, the gastrointestinal decontamination, must be applied if the constipation due to the anticholinergic effect may cause a permanence of the contaminated food in the gastrointestinal tract. In these cases, even if the efficacy in suspected and confirmed cases of botulism intoxication is not clearly demonstrated, upper and lower decontamination with oro-gastric tube and cathartics/whole bowel irrigation could be performed. In order to obtain an effective catharsis is better the use of sorbitol because magnesium salts may exacerbate neuromuscular blockade. The whole bowel irrigation may be challenging because of the ileus toxin-induced; in some cases, neostigmine may be useful in reversing ileus, inhibiting the enzymatic degradation of acetylcholine ^[10]. Activated charcoal administration is also a treatment option in intoxicated patients because it absorbs BoNT/A in vitro ^[11].

3.2. Antidotes

The main goal of the antitoxin treatment is to neutralize the free circulating toxins still unbound at presynaptic level of nerve endings. Additional point is that antitoxin reduces the involvement of new nerve endings: usually the clinical symptoms may progress for up to 12 h after antitoxin administration before an effect is observed ^[12]. The type-specific antitoxins are not able to counteract any other antigen.

As a general approach, antitoxin should be administered as soon as suspect of botulism intoxication is made. The antitoxin is effective also in all the other forms of botulism. For example, animal studies involving inhalation botulism demonstrated that early administration, after an aerosolized release of botulinum toxin (lethal concentration), may be effective ^[13].

Equine-derived antitoxin (since 1970), is the unique antidote available. To date, antidote efficacy is well known in experimental studies in animals. In humans, no randomized controlled studies have been performed to evaluate the action of antitoxin therapy (not ethical approach). To date, the efficacy of antidote is based only by case reports and retrospective studies and clinical experiences.

Morbidity and mortality studies are difficult to perform because of the rarity of the intoxication and of the late diagnosis. The diagnosis is normally performed when the BoNT is already permanently entered and fixed at presynaptic level: in this step antidote is incapable to reverse the endocellular mechanism of the toxin.

Some clinical experience confirmed that the early administration of antitoxin (within 24 h), is more effective in preventing the progression of neurological syndrome and in shortening the duration of mechanical ventilation and intensive care stay ^[14]^[15].

Tacket and co-authors analyzed 132 cases of BoNT/A foodborne botulism (1973–1980), considering the effect of the antitoxin therapy on the outcome of patients. Lower fatality rate (10% vs 15%) was registered in patients that received antitoxin within 24 h after the onset of symptoms. In the group of patients that did not receive antitoxin the fatality rate was very high (46%). Patients that received early antitoxin (<24 h) had a median hospital stay of 10 days compared with 41 days for those who received antitoxin >24 h and 56 days for those not treated ^[14].

Nonetheless, patients may need respiratory support for long period, usually 2–6 weeks even if in some cases may be longer: 58 days and 26 days for botulism due to BoNT/A and BoNT/B, respectively ^[16]. A prolonged rehabilitation program is also needed for some patients with severe intoxication.

The safety and improved clinical outcomes was evaluated in patients treated with BAT during the Investigational New Drug (“compassionate use” IND) study period (2010–2013) ^[17]. A total of 249 persons aged 10 days–88 years (median, 46 years) were treated with BAT. Of these, 17 (7%) were children (median, 6 years; range, 10 days–17 years). None of the 249 treated patients were pregnant or breastfeeding. Botulism was laboratory or epidemiologically confirmed for 104 (42%) patients. Among the 104 patients, all (n = 33) those treated within 24 h of symptom onset (early treatment) survived, while 90% (64/71) of the treated later survived (not statistically significant). In contrast, early BAT treatment was associated with statistically significant shorter hospital (median, 15 vs. 25 days; p < 0.01) and ICU stays (10 vs. 17 days; p = 0.04) compared with later BAT treatment. Among the 249 patients, 9% of patients experienced at least one adverse effect BAT-related: fever (3%), rash (2%), chills (1%) and agitation, edema, slight hypertension, nausea (1%). Bronchospasm, chest pressure, diaphoresis, erythema, increased respiratory rate, “jitteriness”, leukocytosis, mild hypotension, tachycardia, urinary retention and vomiting were each reported once among adults treated group. In pediatric group (n = 17), single cases of fever, agitation/anxiety and an experience of “hurting all over”, were described. Only one severe adverse reaction occurred in a 10-year-old boy (29 kg body weight) who manifested severe hemodynamic instability characterized by bradycardia leading asystole started 90 min after the BAT infusion and rapidly resolved after epinephrine administration. BAT infusion was restarted and after 30 min a second episode of severe bradycardia occurred, at this point the administration was definitively stopped (an estimated 73% of the recommended dose was administered overall).

A single case of serum sickness occurred in a 64-year-old man, which occurred 11 days after BAT administration and physician-reported as mild, self-limited serum sickness characterized by myalgia and arthralgia treated with ibuprofen; the principal investigator also determined it as not serious.

In March 2018 an electronic survey was performed through the European Association of Poisons Centers and Clinical Toxicologists (EAPCCT) with the aim to collect epidemiological data and information on the clinical management, the diagnostic capability and the antidote availability in cases of botulism intoxication in Poison Centers/Poisoning treating facilities (PCs) located in different countries. The survey included 19 items on (i) epidemiological data (registered by PCs during 2015–2017) as well as questions on (ii) availability/location of specific laboratory, (iii) clinical management, (iv) type of antitoxin availability (including dosage/adverse drug reaction) and (v) its location. Fourteen PCs answered to the survey (Austria, Belgium, Czech Republic, Estonia, France, Germany, Greece, Iceland, Ireland, Italy, Poland, Slovenia, South Africa and Switzerland).

Ireland, Estonia, Slovenia and Poland PCs declared no experience with botulism because managed by Infectious Diseases Services, 10 questionnaires were analyzed. Cases of foodborne botulism, infant and adult intestinal botulism and wound botulism were registered by PCs. Specific Labs for diagnosis were available in seven countries (70%), all located in government services (in two countries operative 24H). All PCs, except two, prescribes antidote before the laboratory confirmation. Trivalent equine antitoxin was the unique formulation available and the dosage varied from one to four bottles: no severe acute adverse reactions have been reported. Antitoxin is stocked in PCs/Hospitals/pharmacies and in six countries in strategic stockpiles. In conclusion, PCs experience on botulism is extremely different: some services manage all cases occurring in the country as reference centers, while others refer to Infectious Diseases Services. During the study period (3 years), all forms of botulism have been observed by PCs (including rare forms such as wound and intestinal botulism). PCR diagnosing testing is not routinely available, and in vivo tests remain the gold standard method, even if, accordingly, turnaround time (TAT) is too long to be useful in the first phase of the clinical management. Trivalent equine antitoxin is available in EU, and the administration is safe. On the contrary, the recommended dose varies significantly among countries. Antidote storage in strategic stockpiles may be useful to manage public health emergencies or unconventional events. These data underline the need of a harmonization of management of botulism between PCs would seem appropriate for the future ^[18].

3.3. Supportive Airway Treatment

The milestone of treatment for the cases of botulism intoxication is prompt and supportive care. Because of the high risk of rapid respiratory failure and because respiratory compromise close monitoring of respiration is needed.

As suggested by Arnon and colleagues, in mild cases and when a suspicion of botulism intoxication is made the patients should be put in the reverse Trendelenburg position at 20–25° with cervical support; classically, this position enhance diaphragmatic function decreasing the pressure of abdominal viscera and to reduce the risk of aspiration ^[13].

3.4. Antibiotic Therapy

The antibiotic therapy is not able to interfere with the toxin mechanism of action. In wound botulism form the antibiotic therapy alone remains insufficient; it is indicated when secondary infections are documented. In all forms, aminoglycoside antibiotics and clindamycin may exacerbate the neuromuscular blockade ^[19].

3.5. Experimental Treatments

During the last two decades, several efforts on designing new drugs (e.g., monoclonal antibodies) have been made, especially for blocking the catalytic activity of BoNTs. Efforts have been invested on designing small molecules, peptidic inhibitors, aptamers as well as on testing some natural substances for their anti-botulinum activity ^[7]. Studies on specific inhibitors effective in preventing the neuroparalytic action of BoNTs (irrespectively of their serotype and subtype) which could be used in poisoned patients without knowing the particular type of BoNT are underway and appear to be promising for the future ^[7]^[8]^[20]^[21]^[22]^[23]. Current drug research efforts have mainly focused on BoNT/A and mainly addressed on light chain proteolytic activity. Development of pan-BoNT inhibitors acting independently of BoNT immunological properties and targeting a common step of the intoxication process seems encouraging. In fact, experimental studies on different chemicals or molecules that can interfere with the different stages involving BoNTs mechanisms are available. The new drugs may act as (i) inhibitors of toxin binding, (ii) inhibitors of toxin internalization and trafficking, (iii) inhibitors if toxin translocation, (iv) inhibitors of the toxin disulfide bond reduction, (v) inhibitors of SNARE cleavage by L-chain and (vi) reversal of BoNTs paralysis ^[20].

The binding of BoNTs to receptors located at the presynaptic membrane is the first step of the intoxication. Some antagonists of the ganglioside receptors (e.g., quinic, lectins from Limax Flavus and tricum vulgaris, thearubigin) have been identified. Main limitations of these treatments are the serotype specificity and the short therapeutic window. Other drugs interfere with internalization process (mainly mediated by dynamin-dependent endocytic pathways) and intracellular trafficking (e.g., Dyngo-4a, methylamine hydrochloride, bafilomycin A, nigericin, quinolinol).

Another option is to interact with specific intracellular toxic mechanism (e.g., adamantanes, lomofungin, chicoric acid botulin, benzimidazole acrylonitrile). Inhibitors of SNARE cleavage by L-chain metalloprotease have been studied, but, despite the promising results, none of these molecules concluded the way to be considered an effective drug ^[20]. The last group of molecules considered are those involved in functional recovery of intoxicated nerve terminals. The 3,4 diaminopyridine (3,4-DAP) and analogs, a potassium channel-blocking agent, determine an increase of the presynaptic action potential duration causing an increase Ca²⁺ influx and an increase acetylcholine release ^[24]. The 3,4-diaminopyridine does not cross the blood–brain barrier to a substantial extent ^[9] and its efficacy in not established ^[25]. The only benefit observed regards the improvement in ocular and limb muscle strength, but there has been no benefit on respiratory paralysis ^[26].

Guanidine has been administered in the past to enhance acetylcholine release, but its application, evaluated also in placebo-controlled studies, failed to improve the clinical course of the intoxication ^[27]. Steroids, immunoglobulins, chloroquine, plasmapheresis, have been tried in single cases with debated benefit.

References

Anniballi, F.; Auricchio, B.; Fiore, A.; Lonati, D.; Locatelli, C.A.; Lista, F.; Fillo, F.; Mandarino, G.; De Medici, D. Botulism in Italy, 1986 to 2015. EuroSurveilance 2017, 22, 30550.
Scalfaro, C.; Auricchio, B.; Anniballi, F.; De Medici, D. Foodborne botulism: An evolving public health challenge. Infect. Dis. 2019, 51, 97–101.
Johnson, E.A.; Montecucco, C. Botulism. Neuromuscular junction disorders. In Handbook of Clinical Neurology; Elsevier: Amsterdam, The Netherlands, 2009; pp. 329–364.
Rasetti-Escargueil, C.; Lemichez, E. Public Health risk associated with botulism as foodborne zoonoses. Toxins 2020, 12, 17.
Taylor, S.M.; Wolfe, C.R.; Cox, G.M. Wound botulism complicating internal fixation of a complex radial fracture. J. Clin. Microbiol. 2010, 48, 650–653.
Zhang, S.; Masuyer, G.; Zhang, J.; Shen, Y.; Lundin, D.; Henriksson, L.; Miyashita, S.I.; Martinez-Carranza, M.; Dong, M.; Stenmark, P. Identification and characterization of a novel botulinum neurotoxin. Nat. Commun. 2017, 8, 14130.
Anniballi, F.; Lonati, D.; Fiore, A.; Auricchio, B.; Medici, D. New targets in the search for preventive and therapeutic agents for botulism. Expert Rev.Anti. Infect. 2014, 12, 1075–1086.
Rossetto, O.; Pirazzini, M.; Lista, F.; Montecucco, C. The role of the single interchains disulfide bond in tetanus and botulinum neurotoxins and the development of antitetanus and antibotulism drugs. Cell Microbiol. 2019, 21, e13037.
Howard, L.; Geyer, H.L. Botulism. In Goldfrank’s Toxicologic Emergencies, 11th ed.; Nelson, L.S., Howland, M.A., Lewin, N.A., Smith, S.W., Goldfrank, L.R., Hoffman, R.S., Eds.; Goldfrank’s Toxicologic Emergencies; McGraw-Hill Professional: New York, NY, USA, 2019; pp. 574–591.
Isbister, G.K.; Oakley, P.; Whyte, I.; Dawson, A. Treatment of anticholinergic-induced ileus with neostigmine. Ann. Emerg. Med. 2001, 38, 689–693.
Gomez, H.F.; Johnson, R.; Guven, H.; McKinney, P.; Phillips, S.; Judson, F.; Brent, J. Adsorption of botulinum toxin to activated charcoal with a mouse bioassay. Ann. Emerg. Med. 1995, 25, 818–822.
Dembek, Z.F.; Smith, L.A.; Rusnak, J.M. Botulism: Cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Med. Public Health Prep. 2007, 1, 122–134.
Arnon, S.S.; Schechter, R.; Inglesby, T.V.; Henderson, D.A.; Bartlett, J.G.; Ascher, M.S.; Eitzen, E.; Fine, A.D.; Hauer, J.; Layton, M.; et al. Working Group on Civilian Biodefense. Botulinum toxin as a biological weapon: Medical and public health management. JAMA 2001, 285, 1059–1070.
Tacket, C.O.; Shandera, W.X.; Mann, J.M.; Hargrett, N.T.; Blake, P.A. Equine antitoxin use and other factors that predict outcome in type-A foodborne botulism. Am. J. Med. 1984, 76, 794–798.
Chang, G.Y.; Ganguly, G. Early antitoxin treatment in wound botulism results in better outcome. Eur. Neurol. 2003, 49, 151–153.
Hughes, J.M.; Blumenthal, J.R.; Merson, M.H.; Lombard, G.L.; Dowell, V.R.; Gangarosa, E.J. Clinical features of types A and B food-borne botulism. Ann. Intern. Med. 1981, 95, 442–445.
Yu, P.A.; Lin, N.H.; Mahon, B.E.; Sobel, J.; Yu, Y.; Mody, K.M.; Gu, W.; Clements, J.; Kim, H.; Rao, A.K. Safety and Improved Clinical Outcomes in Patients Treated with New Equine-Derived Heptavalent Botulinum Antitoxin. Clin. Infect. Dis. 2017, 66, S57–S64.
Lonati, D.; Grassi, G.C.; Lindal Baldvinsdottir, L.; Neou, P.; Moens, J.; Kabata, P.M.; De Haro, L.; Oder, M.; Bvar, M.; Rauber-Lüthy, C.; et al. Poison centre data on botulism: Results from an EAPCCT survey. Clin. Toxicol. 2019, 57, 453–454.
Santos, J.I.; Swensen, P.; Glasgow, L.A. Potentiation of Clostridium botulinum toxin by aminoglycoside antibiotics: Clinical and laboratory observations. Pediatrics 1981, 68, 50–54.
Pirazzini, M.; Rossetto, O. Challenges in searching for therapeutics against Botulinum Neurotoxins. Expert Opin. Drug Discov. 2017, 12, 497–510.
Azarnia Tehran, D.; Zanetti, G.; Leka, O.; Lista, F.; Fillo, S.; Binz, T.; Shone, C.C.; Rossetto, O.; Montecucco, C.; Paradisi, C.; et al. Novel Inhibitor Prevents the Peripheral Neuroparalysis of Botulinum Neurotoxins. Sci. Rep. 2015, 5, 17513.
Duregotti, E.; Zanetti, G.; Scorzeto, M.; Megighian, A.; Montecucco, C.; Pirazzini, M.; Rigoni, M. Snake and Spider Toxins Induce a Rapid Recovery of Function of Botulinum Neurotoxin Paralysed Neuromuscular Junction. Toxins 2015, 7, 5322–5336.
Zanetti, G.; Azarnia Tehran, D.; Pirazzini, M.; Binz, T.; Shone, C.C.; Fillo, S.; Lista, F.; Rossetto, O.; Montecucco, C. Inhibition of botulinum neurotoxins interchain disulfide bond reduction prevents the peripheral neuroparalysis of botulism. Biochem. Pharm. 2015, 98, 522–530.
Qiao, J.; Hayes, K.C.; Hsieh, J.T.C.; Potter, P.J.; Delaney, G.A. Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury. J. Neurotrauma 1997, 14, 135–149.
Dock, M.; Ali, A.B.; Karras, A.; Misset, B.; Garrouste-Orgeas, M.; Deletie, E.; Goldstein, F.; Carlet, J. Treatment of severe botulism with 3,4-diaminopiridine. La Presse Med. 2002, 31, 601–602.
Neal, K.R.; Dunbar, E.M. Improvement in bulbar weakness with guanoxan in type-B botulism. Lancet 1990, 335, 1286–1287.
Roblot, P.; Roblot, F.; Fauchere, J.L.; Devilleger, A.; Marechaud, R.; Breux, J.P.; Grollier, G.; Becq-Giraudon, B. Retrospective study of 108 cases of botulism in Poitiers, France. J. Med. Microbiol. 1994, 40, 379–384.

© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.

Upload a video for this entry

Information

Subjects: Toxicology

Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :

Davide Lonati

Azzurra Schicchi

Marta Crevani

Eleonora Buscaglia

Giulia Scaravaggi

Francesca Maida

Marco Cirronis

Valeria Margherita Petrolini

Carlo Alessandro Locatelli

View Times: 436

Update Date: 02 Sep 2022

Table of Contents

Video Upload Options

Confirm